- Home
- GRAN vs BTMD Comparison
GRAN vs BTMD Comparison
Compare GRAN & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAN
- BTMD
- Stock Information
- Founded
- GRAN 2020
- BTMD 2012
- Country
- GRAN Hong Kong
- BTMD United States
- Employees
- GRAN N/A
- BTMD N/A
- Industry
- GRAN
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- GRAN
- BTMD Health Care
- Exchange
- GRAN NYSE
- BTMD Nasdaq
- Market Cap
- GRAN 129.3M
- BTMD 127.8M
- IPO Year
- GRAN 2025
- BTMD N/A
- Fundamental
- Price
- GRAN $5.41
- BTMD $4.32
- Analyst Decision
- GRAN
- BTMD Strong Buy
- Analyst Count
- GRAN 0
- BTMD 1
- Target Price
- GRAN N/A
- BTMD $8.00
- AVG Volume (30 Days)
- GRAN 396.4K
- BTMD 110.5K
- Earning Date
- GRAN 01-01-0001
- BTMD 08-07-2025
- Dividend Yield
- GRAN N/A
- BTMD N/A
- EPS Growth
- GRAN N/A
- BTMD 201.68
- EPS
- GRAN 0.25
- BTMD 0.60
- Revenue
- GRAN $4,731,044.00
- BTMD $199,379,000.00
- Revenue This Year
- GRAN N/A
- BTMD $5.87
- Revenue Next Year
- GRAN N/A
- BTMD $8.59
- P/E Ratio
- GRAN $19.39
- BTMD $7.20
- Revenue Growth
- GRAN 17.00
- BTMD 6.44
- 52 Week Low
- GRAN $4.30
- BTMD $3.04
- 52 Week High
- GRAN $6.70
- BTMD $8.06
- Technical
- Relative Strength Index (RSI)
- GRAN N/A
- BTMD 59.00
- Support Level
- GRAN N/A
- BTMD $3.98
- Resistance Level
- GRAN N/A
- BTMD $4.25
- Average True Range (ATR)
- GRAN 0.00
- BTMD 0.20
- MACD
- GRAN 0.00
- BTMD 0.01
- Stochastic Oscillator
- GRAN 0.00
- BTMD 87.11
About GRAN GRANDE GROUP LIMITED
Grande Group Ltd is a financial service providers in Hong Kong. It is a financial firm that focuses on providing quality corporate finance advisory services to clients. The company in engage in Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities in Hong Kong.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.